Fulcrum therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases. Inspired by patients, Fulcrum drug discovery begins with a deep exploration of disease biology in patient tissue samples. Fulcrum’s proprietary annotated compound library enables them to systematically approach drug discovery in genetically defined diseases. Drug targets are identified that modify gene expression and analyzed computationally using their proprietary database, FulcrumSeek. Fulcrum’s lead program, losmapimod, is being investigated in clinical trials to beat facioscapulohumeral muscular dystrophy.

<p>Fulcrum therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases. Inspired by patients, Fulcrum drug discovery begins with a deep exploration of disease biology in patient tissue samples. Fulcrum’s proprietary annotated compound library enables them to systematically approach drug discovery in genetically defined diseases. Drug targets are identified that modify gene expression and analyzed computationally using their proprietary database, FulcrumSeek.</p>
<p>Fulcrum’s lead program, losmapimod, is being investigated in clinical trials to beat facioscapulohumeral muscular dystrophy.</p>


Fulcrum Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin3
Therapy area: Facioscapulohumeral muscular dystrophy
Drug types: RAR, MUS, GEN, HEM, NEU, CVV
Lead product: Losmapimod
Funding: $125M stock Jan 2023; $144M stock Aug 2021; $68.5M private placement Jun 2020; $72M IPO Jul 2019; $80M B Sep 2018; $55M A Jul 2016

Drug notes:

About:

Jobs: